DiscoveryProbe™ FDA-approved Drug Library: High-Throughput Screening & Drug Repositioning Resource

Executive Summary: The DiscoveryProbe™ FDA-approved Drug Library (SKU: L1021) from APExBIO comprises 2,320 bioactive compounds approved by global regulatory agencies, enabling rapid high-throughput and high-content screening (HTS/HCS) for drug repositioning and novel target discovery (APExBIO). All compounds are pre-dissolved at 10 mM in DMSO, ensuring assay-ready compatibility and storage stability for up to 24 months at -80°C. The library's diversity encompasses receptor agonists, antagonists, enzyme inhibitors, and ion channel modulators, supporting translational research in cancer, neurodegenerative diseases, and complex signaling pathways (Andi et al., 2022). Built-in barcoding and multiple plate/tube formats facilitate seamless integration into automated workflows. Benchmark studies validate the utility of FDA-approved compound libraries in repurposing efforts, including for emerging viral threats and established disease models.

Biological Rationale

Drug repurposing accelerates therapeutic development by leveraging known safety and pharmacology of clinically approved molecules. The DiscoveryProbe™ FDA-approved Drug Library aggregates compounds recognized by the FDA, EMA, HMA, CFDA, and PMDA, or listed in major pharmacopeias. This approach enables systematic screening for new indications, bypassing early-phase toxicity studies. Repurposing is especially valuable in pandemic response and rare disease research, where time and patient populations are limited (Andi et al., 2022). The library supports both phenotypic and target-based screens, facilitating unbiased identification of bioactive chemotypes.

Mechanism of Action of DiscoveryProbe™ FDA-approved Drug Library

The DiscoveryProbe™ FDA-approved Drug Library contains compounds with well-annotated mechanisms, including:

• Receptor agonists and antagonists: Modulate GPCRs, nuclear receptors, and cytokine receptors.
• Enzyme inhibitors: Block kinases, proteases, and metabolic enzymes (e.g., metformin inhibits mitochondrial complex I).
• Ion channel modulators: Alter calcium, sodium, or potassium flux (e.g., antiarrhythmics).
• Signal pathway regulators: Influence pathways such as MAPK, PI3K-AKT, and Wnt/β-catenin (contrast article: deeper mechanistic exploration).

Representative compounds (e.g., doxorubicin, atorvastatin) exhibit validated bioactivity in diverse cell-based and biochemical assays. This mechanistic breadth enables screening for modulators of disease-relevant pathways and identification of off-target effects in complex systems.

Evidence & Benchmarks

• Repurposing of FDA-approved drugs (e.g., remdesivir) for SARS-CoV-2 demonstrates the translational value of such libraries (Andi et al. 2022, DOI).
• High-throughput screening of 2,320-compound sets routinely yields hit rates of 0.5–2% in validated phenotypic assays, expediting lead identification (internal benchmark: robustness in HTS).
• Compounds in the DiscoveryProbe™ FDA-approved Drug Library are pre-dissolved at 10 mM in DMSO, ensuring solubility and immediate assay compatibility (product documentation).
• Long-term stability is validated for 12 months at -20°C and up to 24 months at -80°C, supporting longitudinal studies (product page).
• Benchmark screens using DiscoveryProbe™ compounds have identified new modulators of MAPK signaling and novel targets in neurodegenerative disease models (internal analysis: next-generation MoA studies).

Applications, Limits & Misconceptions

The DiscoveryProbe™ FDA-approved Drug Library is optimized for:

• High-throughput and high-content screening (HTS/HCS) in cell-based and biochemical assays
• Drug repositioning and target deconvolution workflows
• Pharmacological target identification in oncology, neurodegeneration, and pathway regulation (internal: translational benchmarking)
• Validation of disease models using clinically relevant molecules

Common Pitfalls or Misconceptions

• Not all compounds are universally active in every cell type or disease model—contextual validation is essential.
• Off-target effects may confound primary screening results; orthogonal secondary assays are recommended.
• The library is not a substitute for de novo chemistry when novel scaffolds are needed.
• Assay interference from DMSO or compound autofluorescence should be controlled for in HCS workflows.
• Regulatory approval does not guarantee efficacy in new indications without appropriate validation.

Workflow Integration & Parameters

The DiscoveryProbe™ FDA-approved Drug Library ships in 96-well microplates, deep-well plates, or 2D barcoded tubes, pre-dissolved at 10 mM in DMSO. Storage at -20°C is suitable for 12 months; -80°C extends stability to 24 months. The library integrates into automated screening platforms using standard liquid handling protocols. Barcoding supports sample tracking in large-scale HTS. Shipping occurs on blue ice for evaluation sizes or at room temperature upon request. APExBIO provides comprehensive QC data and batch documentation. Researchers can combine this library with genetic or phenotypic screens for expanded target ID capabilities (internal: integration strategies).

Conclusion & Outlook

The DiscoveryProbe™ FDA-approved Drug Library (L1021) from APExBIO is a validated, versatile tool for high-throughput pharmacological discovery. Its clinical annotation, solubility, and cross-platform compatibility enable rapid drug repositioning and mechanistic insights in disease research. As emergent threats (e.g., SARS-CoV-2) and complex diseases demand agile translational strategies, such libraries will remain pivotal in both academic and industrial innovation. For complete technical details or to order, see the DiscoveryProbe™ FDA-approved Drug Library product page.